Long-Term Risk of Cardiovascular Disease in 5-Year Survivors of Testicular Cancer
Top Cited Papers
- 20 January 2006
- journal article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (3), 467-475
- https://doi.org/10.1200/jco.2005.02.7193
Abstract
Purpose To evaluate the long-term risk of cardiovascular disease (CVD) in survivors of testicular cancer (TC). Patients and Methods We compared CVD incidence in 2,512 5-year survivors of TC, who were treated between 1965 and 1995, with general population rates. Treatment effects on CVD risk were quantified in multivariate Cox regression analysis. Results After a median follow-up of 18.4 years, 694 cardiovascular events occurred, including 141 acute myocardial infarctions (MIs). The standardized incidence ratio (SIR) for coronary heart disease was 1.17 (95% CI, 1.04 to 1.31), with 14 excess cases per 10,000 person-years. The SIR for MI was significantly increased in nonseminoma survivors with attained ages of less than 45 (SIR = 2.06) and 45 to 54 years (SIR = 1.86) but significantly decreased for survivors with attained ages of 55 years or older (SIR = 0.53). In Cox analysis, mediastinal irradiation was associated with a 3.7-fold (95% CI, 2.2- to 6.2-fold) increased MI risk compared with surgery alone, whereas infradiaphragmatic irradiation was not associated with an increased MI risk. Cisplatin, vinblastine, and bleomycin (PVB) chemotherapy (CT) was associated with a 1.9-fold (95% CI, 1.7- to 2.0-fold) increased MI risk, and bleomycin, etoposide, and cisplatin (BEP) CT was associated with a 1.5-fold (95% CI, 1.0- to 2.2-fold) increased CVD risk and was not associated with increased MI risk (hazard ratio = 1.2; 95% CI, 0.7 to 2.1). Recent smoking was associated with a 2.6-fold (95% CI, 1.8- to 3.9-fold) increased MI risk. Conclusion Nonseminomatous TC survivors experience a moderately increased MI risk at young ages. Physicians should be aware of excess CVD risk associated with mediastinal radiotherapy, PVB CT, and recent smoking. Intervention in modifiable cardiovascular risk factors is especially important in TC survivors. Whether BEP treatment increases CVD risk should be evaluated after more prolonged follow-up.Keywords
This publication has 42 references indexed in Scilit:
- Weekly cisplatin-epirubicin-paclitaxel (PET) vs. triweekly epirubicin-paclitaxel (ET) in metastatic breast cancer (MBC). Interim analysis of the SICOG 9908 phase III trialJournal of Clinical Oncology, 2004
- Increased mortality rates in young and middle-aged patients with malignant germ cell tumoursBritish Journal of Cancer, 2004
- Cardiovascular Disease as a Long-Term Complication of Treatment for Testicular CancerJournal of Clinical Oncology, 2003
- Equivalence of Three or Four Cycles of Bleomycin, Etoposide, and Cisplatin Chemotherapy and of a 3- or 5-Day Schedule in Good-Prognosis Germ Cell Cancer: A Randomized Study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research CouncilJournal of Clinical Oncology, 2001
- Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 2000
- Cardiovascular Morbidity in Long-Term Survivors of Metastatic Testicular CancerJournal of Clinical Oncology, 2000
- Testicular cancerCurrent Problems in Cancer, 1998
- Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy.Journal of Clinical Oncology, 1994
- Cardiovascular mortality in a randomized trial of adjuvant radiation therapy versus surgery alone in primary breast cancerInternational Journal of Radiation Oncology*Biology*Physics, 1992
- Mortality patterns over 34 years of breast cancer patients in a clinical trial of post-operative radiotherapyClinical Radiology, 1989